
|Slideshows|May 18, 2018
EMPA-REG OUTCOME: Analysis in Women with T2DM and CVD
Author(s)Veronica Hackenthal, MD
A recent trial found that empagliflozin can reduce the risk of cardiovascular deaths in type 2 diabetes patients; are results similar in men and women?
Advertisement
  Â
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
4
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
5


























































